抗结核新药SQ109、PA-824、OPC-67683与R207910研究进展

Advances in new anti-tuberculosis drugs:SQ109,PA-824,OPC-67683 and R207910

近10余年来，由于HIV／AIDS的流行、移民、多种耐药结核菌的增多，以及不少国家和地区对结核病控制的忽视等因素，全球结核病形势急剧恶化，无论发达国家或发展中国家，结核病病人数都在增加。据世界卫生组织估算，全球已有近20亿人口受结核菌的感染，有2000万结核病人，每年新发生的结核病病人数为800～1000万人。结核病是一个全球性的严重公共卫生问题，现已引起国际社会的极大关注。

Tuberculosis has always been one of the most serious public health problems in the world. In recent years, new attention is focused on some increasing factors, such as drug-tolerance and correlation to HIV. As the result, several promising anti-tuberculosis agents have been found and launched a series of clinical trails. Herein, we try to review them to give some clues to the clinical anti-tuberculosis in china.